This is from the article that was published about exosomes in The Journal of Translational Medicine:
"Conclusion
The Hemopurifier™ cartridge can enter the cancer therapeutics
arena with relative ease due to several factors.
Firstly, the cartridge is already produced under Good
Manufacturing Practices with clinical safety data available,
albeit for different indications. Secondly, the cartridge is
compatible with standard dialysis systems which are
present at every major medical institution. Thirdly, the
patient population whose treatment is proposed with this
novel approach has few or no treatment alternatives.
Fourthly, the Hemopurifier™ cartridge can be used not
only as a monotherapy, but also as an adjuvant to currently
used immunotherapeutic approaches. The commercialization
of therapies as adjuvants to existing
therapies is well-accepted in the industry, as seen in the
approval of Herceptin and Avastin for use with specific
chemotherapeutic agents.
In conclusion, the use of the Hemopurifier™ as a means of
de-repressing immune functions in cancer patients is a
novel, easily implemented approach to cancer therapeutics
that will not only provide an alternative to the currently
ineffective approaches, but also provide a
framework for development of strategies that may benefit
cancer patients in a multidimensional manner."
If anyone would like the full article, PM me your e-mail and I will send it right away.
Exosomes as a tumor immune escape mechanism: possible
therapeutic implications
Thomas E Ichim*1,2,9, Zhaohui Zhong†3, Shalesh Kaushal†4, Xiufen Zheng2,
Xiubao Ren5, Xishan Hao5, James A Joyce6, Harold H Hanley6,
Neil H Riordan1, James Koropatnick2, Vladimir Bogin1, Boris R Minev7,8,
Wei-Ping Min2 and Richard H Tullis6
